Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT

Background In REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial), icosapent ethyl (IPE) versus placebo) reduced cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina requiring hospitalization, but was associated with i...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Brian Olshansky, Deepak L. Bhatt, Michael Miller, Ph. Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Ralph T. Doyle, Rebecca A. Juliano, Lixia Jiao, Peter R. Kowey, James A. Reiffel, Jean‐Claude Tardif, Christie M. Ballantyne, Mina K. Chung
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2023-03-01
coleção:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Assuntos:	atrial fibrillation bleeding eicosapentaenoic acid icosapent ethyl prevention
Acesso em linha:	https://www.ahajournals.org/doi/10.1161/JAHA.121.026756
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!